Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
Gerwyn Morris, Eugene Athan, Ken Walder, Chiara C Bortolasci, Adrienne O'Neil, Wolf Marx, Michael Berk, Andre F Carvalho, Michael Maes, Basant K Puri
Life Sciences | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2020
The possibility is examined that immunomodulatory pharmacotherapy may be clinically useful in managing the pandemic coronavirus disease 2019 (COVID-19), known to result from infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-sense single-stranded RNA virus. The dominant route of cell entry of the coronavirus is via phagocytosis, with ensconcement in endosomes thereafter proceeding via the endosomal pathway, involving transfer from early (EEs) to late endosomes (LEs) and ultimately into lysosomes via endolysosomal fusion. EE to LE transportation is a rate-limiting step for coronaviruses. Hence inhibition or dysregulation of endosomal trafficking could po..View full abstract
Awarded by NHMRC Senior Principal Research Fellowship
MB is supported by a NHMRC Senior Principal Research Fellowship 1059660.